Stock Rating Report for AGEN
|
|
Stock Information
| Ticker |
AGEN |
| Company Name |
Agenus Inc |
| Current Price |
$2.93 |
| Previous Close |
$2.93 |
| Industry |
Biotechnology |
| Sector |
HEALTHCARE |
| Long Stop Loss |
Members Only |
| Short Stop Loss |
Members Only |
| Expected Move |
Members Only |
| Optionable? |
Yes
|
StockProphet Ratings
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
Sector Risks
Chart
We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for AGEN. However, we only show it to our subscribers.
We update our ratings and stop losses EVERY WEEK.
Don't miss out on what we recommend for Agenus Inc next week. Sign up today and start making money!
Demand Fundamentals
|
Demand Technicals
Company Profile
Agenus Inc., a biotechnology company, develops and commercializes immunotherapies for cancer and infectious diseases. It markets Oncophage vaccine for the treatment of adjuvant renal cell carcinoma (kidney cancer). The company also has various product candidates under development, which include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of non-small cell lung cancer, melanoma, malaria, and singles, as well as in Phase II clinical trials for the treatment of Alzheimer's disease. In addition, the company's product candidates under development comprise Prophage, which is in Phase II clinical trials for the treatment of glioma (brain cancer) and pediatric neurological tumors- and HerpV, which is in Phase I clinical trials for the treatment of genital herpes. Further, it has various other undisclosed vaccines in Phase I and II studies. The company was formerly known as Antigenics Inc. and changed its name in January, 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
|
Latest News
| Mon, 06 Feb 2012 12:00:00 GMT | Agenus to Present at BIO CEO & Investor Conference | | Mon, 16 Jan 2012 09:23:19 GMT | Pharma Leaders Emerging In Immunotherapy Approach To Fighting Glioblastoma | | Mon, 09 Jan 2012 19:15:52 GMT | Dendreon's on a Huge Run Following Preannouncement | | Thu, 05 Jan 2012 19:22:45 GMT | Coverage initiated on Agenus by William Blair | | Wed, 04 Jan 2012 21:07:33 GMT | Agenus initiated with an Outperform at William Blair | | Wed, 04 Jan 2012 21:07:33 GMT | Agenus initiated with an Outperform at William Blair | | Wed, 04 Jan 2012 12:00:00 GMT | Agenus to Present at OneMedForum San Francisco 2012 | | Wed, 04 Jan 2012 12:00:00 GMT | Agenus to Present at OneMedForum San Francisco 2012 | | Tue, 20 Dec 2011 11:00:00 GMT | Agenus and NewVac Enter Into Agreement in the Area of Personalized Cancer Vaccines | | Mon, 19 Dec 2011 12:00:35 GMT | AGENUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits | | Mon, 19 Dec 2011 12:00:00 GMT | Agenus and ChemRar Enter Into Agreement in the Area of Personalized Cancer Vaccines | | Thu, 15 Dec 2011 16:17:35 GMT | 2012 Preview: Cancer Immunotherapy Catalysts | | Mon, 12 Dec 2011 14:14:07 GMT | AGENUS INC Files SEC form 8-K, Change in Directors or Principal Officers | | Thu, 17 Nov 2011 14:28:41 GMT | AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits | | Wed, 16 Nov 2011 12:00:00 GMT | Agenus Vaccine for Brain Cancer Highlighted at Current State of the Art Session at the Annual Society for Neuro-Oncology (SNO) Meeting | | Thu, 10 Nov 2011 18:04:22 GMT | AGENUS INC Financials | | Fri, 04 Nov 2011 19:05:25 GMT | AGENUS INC Files SEC form 10-Q, Quarterly Report | | Thu, 27 Oct 2011 12:24:46 GMT | AGENUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits | | Tue, 18 Oct 2011 19:50:22 GMT | Malaria vaccine is effective in large trial | | Tue, 18 Oct 2011 19:13:45 GMT | UPDATE 2-World's first malaria vaccine works in major trial | News provided by Yahoo! Finance |
|
|
|
|
